CRAYON
19.8.2020 06:02:10 CEST | Business Wire | Press release
Crayon, a global leader in digital transformation services, is proud to announce it has entered into a Strategic Collaboration Agreement with Amazon Web Services (AWS). This relationship will help both Crayon and AWS to bring innovation to clients faster, and help them best leverage the transformational power, economics, and agility of the cloud.
Enterprise customers are increasingly relying on AWS to achieve their target business outcomes faster by transitioning to a modern, optimized, cloud-based model. Crayon has a strong track record in migration strategy, implementation, total cost optimization, and cloud economics services. This relationship will help customers have a best-in-class service team to understand what software and infrastructure they have and how to best manage their overall IT estate once they are operating in the cloud.
According to global research and advisory firm Gartner Group, Inc. , spending on cloud infrastructure is projected to grow by nearly 60% in the next two years, while investments in data center systems is projected to decline. This means organizations will have to be smart about their IT investments. Crayon can provide the guidance, tools and expertise to properly manage costs, governance and security in the cloud.
“Collaborating with AWS has been a part of our strategy to build an even stronger commitment to our customers’ success. Alongside AWS we will deliver services to enable our customers to digitally transform, achieve operational efficiencies, and maximize cost optimization to strengthen their performance,” says Crayon CEO Torgrim Takle. “Putting the customer first is in the DNA of Crayon and AWS, and together we will serve more organizations worldwide with world-class solutions.”
Crayon has spent the last several years developing and diversifying its cloud services offerings. Both Crayon and AWS expect this latest collaboration to benefit customers wanting to optimize their overall IT estate utilizing best practices in their cloud adoption framework.
One of those customers who has seen first-hand the power of Crayon and AWS working together is The Future Group, a global company that handles many high-profile projects including those from The Weather Channel and the Super Bowl.
"At The Future Group we have had the great fortune to be able to draw on Crayon's deep knowledge in software development, cloud operations and AWS's wide range of services, to help us build and deliver one of the world's most advanced Mixed Reality solutions for the broadcast industry in record time," said Marcus Brodersen, CEO in The Future Group.
Crayon serves customers in more than 45 countries spanning Europe, the Middle East, Africa, North America, and the Asia-Pacific region.
“Crayon has demonstrated a longstanding commitment of putting customers first and helping them find effective ways to optimize the costs of their IT spend,” said Doug Yeum, Head of Worldwide Channel and Alliances, Amazon Web Services, Inc. “We are delighted to collaborate with Crayon to continue guiding customers through their cloud adoption journey.”
About Crayon:
Crayon helps customers build the commercial and technical foundation for a successful digital transformation journey through a reliable services framework allowing our customers to right-size and optimize their IT estates to unlock technology’s potential and innovation. Headquartered in Oslo, Norway, Crayon has over 1600 employees across approximately 50 locations worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005014/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom